Accessibility Menu
PepGen logo

PepGen(NASDAQ) PEPG

Market Cap$123.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-87%
5 YearN/A
1 Year+29%
1 Month-1%
$1.77
+3.22%
+0.05Today
PepGen last closing stock price
MetricPriceDate
Last closeUSD 1.782026-07-30
PepGen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.24%USD 2.102026-07-23
1 month-1.11%USD 1.802026-06-30
3 month+1.71%USD 1.752026-05-01
Year to date-72.66%USD 6.512025-12-31
1 year+28.99%USD 1.382025-07-30
3 year-70.28%USD 5.992023-07-31
Since inception-86.73%USD 12.892022-05-06

PepGen Financials at a Glance

Market Cap

$123.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$77.22M

EPS (TTM)

-$1.75

P/E Ratio

-1.02

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$1.77

Volume

467,033

Open

$1.72

Previous Close

$1.78

Daily Range

$1.68 - $1.78

52-Week Range

$1.01 - $7.80

Estimated Earnings Date

Aug 6, 2026

PEPG News

Foolcom-Featured.png

PepGen (PEPG) Q2 Loss Narrows 19.5%

Motley Fool Markets TeamAug 7, 2025

PEPG: Motley Fool Moneyball Superscore

45

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PepGen

PepGen develops medicines for people with severe muscle and nerve diseases. Its main drug candidates aim to help those with rare genetic conditions. The company focuses on improving how these medicines reach affected cells.

What’s in the PepGen Medicine Cabinet?

  • PGN-EDODM1: Experimental treatment for myotonic dystrophy type 1, a rare muscle disorder; no revenue contribution as of June 2025.
  • PGN-EDO51: Investigational drug for Duchenne muscular dystrophy; development stopped in May 2025 after trial results.
  • EDO Platform: Technology that helps deliver genetic medicines into cells more effectively; supports all current research.
  • Other DMD Candidates: PGN-EDO53, PGN-EDO45, and PGN-EDO44 for Duchenne muscular dystrophy; all discontinued in May 2025.

Growth Spurts and Strategic Pivots

  • Discontinued all Duchenne muscular dystrophy research in May 2025 after clinical trial setbacks.
  • Shifted focus to myotonic dystrophy type 1 program in 2025, with ongoing Phase 1 and 2 trials.
  • Raised $76.4 million in February 2024 and $9.9 million through an at-the-market program in 2024.
  • Filed shelf registrations in June 2023 ($300 million) and June 2024 ($250 million) for future fundraising flexibility.

PepGen’s Secret Sauce (No Actual Sauce Involved)

PepGen’s main strength is its Enhanced Delivery Oligonucleotide platform, which helps genetic medicines enter cells more efficiently. The company targets rare diseases with few treatment options, focusing resources on a single lead program after discontinuing others. Its approach relies on unique delivery technology and regulatory designations that may speed up development for rare conditions.

Five Things You Need to Know

  • No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Operating loss was $24 million in Q2 2025, an improvement of 21.3% versus Q2 2024.
  • Cash and marketable securities totaled $74.7 million as of June 30, 2025.
  • R&D expenses were $43.8 million for the first half of 2025, up $4 million year-over-year.
  • Management expects current funds to last into Q2 2026.

Bottom Line

PepGen has narrowed its focus to one main drug program after ending others. The company’s future depends on its ability to advance this lead candidate and secure new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

56

CEO

James Gregg McArthur, PhD

Website

pepgen.com

Headquarters

Boston, MA 02118, US

PEPG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-59.89%

Return on Capital

-56.92%

Return on Assets

-49.40%

Earnings Yield

-98.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$123.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.17M

Volume

467.03K

Avg. Volume

877.57K

Financials (TTM)

Gross Profit

-$1.72M

Operating Income

-$81.23M

EBITDA

-$75.99M

Operating Cash Flow

-$77.13M

Capital Expenditure

-$139.00K

Free Cash Flow

-$77.27M

Cash & ST Invst.

$132.30M

Total Debt

$16.56M

PepGen Performance Analysis

PepGen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
PepGen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
PepGen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.91139.2%
20232023-12-31USD -3.3013.4%
20242024-12-31USD -2.85-13.8%
20252025-12-31USD -2.12-25.5%
PepGen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3023.9%
Q32025-09-3021.4%
Q42025-12-3121.8%
Q12026-03-312.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$319.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$123.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.20M

N/A

Employees

56

N/A

Net Income

-$17.76M

+41.2%

EBITDA

-$17.43M

+39.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$132.30M

+35.3%

Total Debt

$16.56M

-9.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$13.35M

-11.9%

Short Term Debt

$3.21M

+3.0%

Return on Assets

-49.40%

N/A

Return on Invested Capital

-55.14%

N/A

Free Cash Flow

-$18.43M

+20.1%

Operating Cash Flow

-$18.43M

+19.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NKTXNkarta, Inc.
$2.15+0.94%
MOLNMolecular Partners AG
$4.18+6.36%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$9.05+1.46%
ALECAlector, Inc.
$1.62+6.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About PEPG

What is the current price of PepGen?

PepGen is trading at $1.78 per share.

What is the 52-week range for PepGen?

Over the past 52 weeks, PepGen has traded between $1.01 and $7.80.

How much debt does PepGen have?

As of the most recent reporting period, PepGen reported total debt of $16.56M.

How much cash does PepGen have on hand?

PepGen reported $42.15M in cash and cash equivalents in its most recent financial results.

What is PepGen’s dividend yield?

PepGen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services